FDA Drug Safety Communication: FDA requires drug interaction studies with potassium-lowering drug Kayexalate (sodium polystyrene sulfonate)

FDA requires drug interaction studies with potassium-lowering drug Kayexalate (sodium polystyrene sulfonate)

Today, FDA issued a Drug Safety Communication concerning Kayexalate (sodium polystyrene sulfonate or SPS) to alert the public that FDA is requiring the manufacturer of Kayexalate to conduct studies to evaluate Kayexalate’s potential to bind to other orally administered medications, therebypotentially decreasing the effects of those medications. To reduce this potential risk, prescribers and patients should consider separating Kayexalate dosing from other orally administered medications by at least 6 hours. To read more about this topic, please see the Drug Safety Communication. 

Helene Clayton-Jeter, O.D.
Office of Health and Constituent Affairs
Food and Drug Administration

For more information about the Cardiovascular & Endocrine Liaison Program visit the FDA Patient Network